Metagenomi Therapeutics, Inc. (MGX) Free cash flow 2023–2025
Metagenomi Therapeutics, Inc. (MGX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$89.5MFY2025 · since FY2023: -$101.2M → -$89.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$89.5M | +20.3% |
| FY2024 | -$112.2M | -10.8% |
| FY2023 | -$101.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice